Happy Thanksgiving! #thanksgiving #TurkeyDayFun
关于我们
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com
- 网站
-
https://www.origene.com
OriGene的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Rockville，MD
- 类型
- 私人持股
- 创立
- 1996
- 领域
- Cancer pathology、Expression cDNA clones、Full-length human proteins、Primary antibodies、Multiplex assays、Gene synthesis Service、Antibody and Protein Optimization和Cancer tissue repository (Blocks/sections/RNA/DNA)
地点
-
主要
获取路线
9620 Medical Center Drive,
Suite 200
US，MD，Rockville，20850
OriGene员工
动态
-
Learn more about the four elements of IHC and how you can elevate your research, including this application in your everyday research. Click here to learn more: https://hubs.ly/Q02Zy0j60 #IHC #Immunohistochemistry #LabLife
-
We are excited to share this week’s #CitationMonday publication. Read the Publication: https://lnkd.in/eMXzeRVp Featured OriGene Product: https://lnkd.in/e-82W2iv
-
-
The FDA recently granted accelerated approval to tarlatamab (Imdelltra) for specific individuals with small-cell lung cancer. OriGene is excited to see this innovative therapy, a bispecific T-cell engager (BiTE), work by directing the body's immune system to attack cancer cells. At OriGene, we're committed to staying informed about the latest advancements in cancer research. This breakthrough highlights the potential of targeted therapies in the fight against this aggressive disease. #cancerresearch #lungcancer #biotechnology #drugdiscovery #immunotherapy
The FDA recently granted accelerated approval to tarlatamab (Imdelltra) for some individuals with small cell lung cancer, the most aggressive form of lung cancer. Learn more: https://go.nih.gov/ND04aus Media Description: Tarlatamab is a bispecific T-cell engager (BiTE), a two-armed drug that simultaneously latches onto tumor cells and T cells, bringing them close together and helping the T cells recognize and destroy cancer cells. Credit: Adapted and used with permission from Amgen.
-
-
OriGene is impressed by the groundbreaking discovery published in Nature by scientists at the University of Copenhagen. Their identification of a new weight loss drug target offers hope for more effective and tolerable treatments for obesity and type 2 diabetes. It's exciting to see research addressing the limitations of current therapies, mainly side effects like nausea and vomiting. We look forward to future developments in this field and their potential impact on global health. Check our NK2R-focused products here: https://shorturl.at/FzCOk #obesity #NK2R #naturejournal
????????? ????????????: ?????? ???????????? ???????? ???????? ???????????? ?????????? ???????????? ?????? ???????????? ???????????????? – ?????????????? ?????? ???????????? ?????? ???????????????? ? ???Millions of people around the world benefit from weight loss drugs based on the incretin hormone GLP-1. These drugs also improve kidney function, reduce the risk of fatal cardiac events, and are linked to protection against neurodegeneration. ? ???However, many people stop taking the drugs due to common side effects, including nausea and vomiting. Studies also show that incretin-based therapies like Wegovy and Mounjaro are much less effective at lowering weight in people living with both obesity and type 2 diabetes – a group numbering more than 380 million people globally. ? ???In a study published in Nature Magazine, scientists from the University of Copenhagen describe a powerful new drug candidate that lowers appetite without loss of muscle mass or side effects like nausea and vomiting. And, unlike the current generation of treatments, the drug also increases the body’s energy expenditure – the capacity of the body to burn calories. ? ???"While GLP-1-based therapies have revolutionized patient care for obesity and type 2 diabetes, safely harnessing energy expenditure and controlling appetite without nausea remain two Holy Grails in this field. By addressing these needs, we believe our discovery will propel current approaches to make more tolerable, effective treatments accessible to millions more individuals,” says Associate Professor Zach Gerhart-Hines from the NNF Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. ? Read more about the study, below??? ? https://lnkd.in/de-wyfcd ? ------ ? PhD Student Frederike Sass and Tao Ma are co-first authors of the study. Corresponding authors are CBMR's Associate Professor Zach Gerhart-Hines and Jakob Bondo Hansen, Head of Research at Embark Laboratories. ? Contributing authors are: Lucile Dollet, Jenny M. Brown, PhD, Astrid Linde Basse, Hayley Burm, Mette Korre Andersen, Thomas Svava Nielsen, PhD, Abigail Tomlinson, Oksana Dmytriyeva, Dan Ploug Christensen, Camilla Trang Vo, Dylan Rausch, Cecilie Kynding, María Gestal Mato, Kim Sj?berg, Jacob Emil Petersen, Artem Pavlovskyi, Ida Moltke, Marit Eika J?rgensen, Anders Albrechtsen, Niels Grarup, M. Madan Babu, Patrick Rensen, Sander Kooijman, Randy Seeley, Anna Worthmann, J?rg Heeren, Tune Pers, Torben Hansen, Magnus Gustafsson, Mads Tang-Christensen, Tuomas Kilpel?inen, Martin Myers, Paul Kievit, Thue Schwartz (author list continued in the comments).
-
Elevate Your Lentiviral Research with OriGene! ?? Are you looking to streamline your lentivirus production? Our comprehensive range of accessories is now 30% off until the end of the year! Boost your experiments with: ??Optimized packaging kits ??Efficient concentrators ??Stabilizers for long-term storage ??Control particles for precise titrations ??Specialized transfection reagents Use code ??????????????-???? to claim your discount here: https://hubs.ly/Q02YXnGW0
-
-
TrueOrf Gold cDNA clones are expression-validated and sequence-verified for reliable results. Avoid risks with non-validated clones—save time and resources. They are: ??Expression validated by Western Blot ??Transfection Ready ??Easily shuttled into over 100+ Vectors Watch the video below and learn more about OriGene's TrueOrf cDNA clones! https://bit.ly/48QMTsY #labresearch #research #cDNA #vector #clones
-
Lung cancer remains a major global health concern. ?? OriGene's Tissue Biorepository offers a valuable resource for researchers studying this deadly disease. Our collection includes a wide range of human lung tissue samples, including cancer, normal, and disease-specific tissues. Featured Products from Human Lung Tissue Include: ??Lung Genomic DNA: https://lnkd.in/eMzw7k-E ??Lung Total RNA: https://lnkd.in/ea7pWReM ??Lung Tissue Protein Lysates: https://lnkd.in/eZDCaYUk ??Lung FFPE Sections/Slides: https://lnkd.in/eizvkqJp Let's work together to find a cure: https://hubs.ly/Q02YJr590 #LungCancerAwarenessMonth #LungCancer #CancerResearch #TissueBiorepository
-
-
We are excited to share this week’s #CitationMonday publication. This week, we highlight a publication by Dr. Yang Gao from the Institute of Cancer Research, China, in Cancer Cell. The study uses single-cell RNA sequencing to analyze human fibroblasts across tissues and disease states, identifying 20 distinct fibroblast subtypes. The research highlights the roles of specific subtypes like LRRC15+ and MMP1+ myofibroblasts in promoting immunosuppressive tumor environments, while PI16+ fibroblasts may counteract tumor growth. These insights improve our understanding of fibroblast biology and suggest targeted therapeutic approaches for cancer. OriGene’s TrueMAB EPCAM Mouse Monoclonal Antibody was part of the antibody cocktail used to identify and sort fibroblasts by excluding epithelial cells (EPCAM+), endothelial cells (CD31+), and immune cells (CD45+). Featured product: https://lnkd.in/gYNWBJeF Read the publication: https://lnkd.in/gfXAsKy7
-
-
A significant breakthrough in pancreatitis research! Mayo Clinic scientists have discovered a way to prevent organ damage in acute pancreatitis by blocking the breakdown of harmful fatty acids. This groundbreaking research could lead to new treatments for this severe condition and improve the lives of millions. #pancreatitis #research #mayoclinic
Researchers at Mayo Clinic have discovered a way to prevent organ damage in acute pancreatitis by blocking the breakdown of triglycerides into harmful fatty acids. This groundbreaking study, published in the Journal of Clinical Investigation, opens new doors for treating this common and severe condition. Learn more: https://mayocl.in/48PkVOd
-